Abstract:Multifunctional platinumIV anticancer prodrugs have the potential to enrich the anticancer properties and overcome the clinical problems of drug resistance and side effects of platinumII anticancer agents. Herein, we develop dual and triple action platinumIV complexes with targeted and biological active functionalities. One complex (PFL) that consists of cisplatin, tegafur, and lonidamine exhibits strong cytotoxicity against triple negative breast cancer (TNBC) cells. Cellular uptake and distribution studies reveal that PFL mainly accumulates in mitochondria. As a result, PFL disrupts the mitochondrial ultrastructure and induces significant alterations in the mitochondrial membrane potential, which further leads to an increase in production of reactive oxygen species (ROS) and a decrease in ATP synthesis in MDA-MB-231 TNBCs. Western blot analysis reveals the formation of ternary complex of thymidylate synthase, which shows the intracellular conversion of tegafur into 5-FU after its release from PFL. Furthermore, treatment with PFL impairs the mitochondrial function, leading to the inhibition of glycolysis and mitochondrial respiration and induction of apoptosis through the mitochondrial pathway. The RNA-sequencing experiment shows that PFL can perturb the pathways involved in DNA synthesis, DNA damage, metabolism, and transcriptional activity. These findings demonstrate that PFL intervenes in several cellular processes including DNA damage, thymidylate synthase inhibition, and perturbation of the mitochondrial bioenergetics to kill the cancer cells. The results highlight the significance of a triple-action prodrug for efficient anticancer therapy for TNBCs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.inorgchem.0c01736?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.inorgchem.0c01736</a>.Supporting experimental methods; characterization of the complexes; stability data; reduction of the complexes by AA; Hoechst staining; ATP assay and RNA-seq data (<a class="ext-link" href="/doi/suppl/10.1021/acs.inorgchem.0c01736/suppl_file/ic0c01736_si_001.pdf">PDF</a>)List of genes that are up-regulated or down-regulated (<a class="ext-link" href="/doi/suppl/10.1021/acs.inorgchem.0c01736/suppl_file/ic0c01736_si_002.xlsx">XLSX</a>)List of transcription factor (TF) genes that are up-regulated or down-regulated (<a class="ext-link" href="/doi/suppl/10.1021/acs.inorgchem.0c01736/suppl_file/ic0c01736_si_003.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Discovery of Novel Mifepristone Derivatives Via Suppressing KLF5 Expression for the Treatment of Triple-Negative Breast Cancer.

Mifepristone Derivative Fzu-00,003 Suppresses Triple-Negative Breast Cancer Cell Growth Partially Via Mir-153-Klf5 Axis

Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: Comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex

Treatment of Endometriosis with Mifepristone Mediated by Nanostructured Lipid Carriers

Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression

Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer

Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer

Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer

A Novel Small-Molecule Antagonizes PRMT5-mediated KLF4 Methylation for Targeted Therapy

Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer

Discovery of Novel PI3K/CDK2 Dual Inhibitor Based on 7-Azaindole Derivatives As a Promising Strategy for Triple-Negative Breast Cancer Therapy

Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer

Synthesis and mechanism of action of new purine derivatives against triple negative breast cancer

Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides As Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC)

Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer

Discovery of Novel Azaphenothiazine Derivatives to Suppress Endometrial Cancer by Targeting GRP75 to Impair Its Interaction with IP3R and Mitochondrial Ca2+ Homeostasis

Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer

Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer

Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2h,4h)-dione Analogues: Development of Potent Eef2k Degraders Against Triple-Negative Breast Cancer.